HDAC2 as a new target to improve schizophrenia treatment

Expert Review of Neurotherapeutics

Volumn 13, Issue 1, 2013, Pages 1-3

  Kurita, Mitsumasa ^a   Holloway, Terrell ^a   González Maeso, Javier ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

5 HT2A receptor; antipsychotic drugs; epigenetics; G protein coupled receptor; histone deacetylase; metabotropic glutamate 2 receptor; schizophrenia; serotonin

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; HISTONE DEACETYLASE 2; LYSERGIDE; METABOTROPIC RECEPTOR 2; NEUROLEPTIC AGENT; OLANZAPINE; PSILOCYBINE; RISPERIDONE; SEROTONIN; SEROTONIN 2A RECEPTOR; VALPROIC ACID; VORINOSTAT;

CHROMATIN STRUCTURE; COGNITIVE DEFECT; DNA SEQUENCE; DRUG EFFECT; DRUG RECEPTOR BINDING; EPIGENETICS; FRONTAL CORTEX; GENE EXPRESSION; HISTONE MODIFICATION; HUMAN; NERVE CELL PLASTICITY; NONHUMAN; PROMOTER REGION; PROTEIN TARGETING; REVIEW; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; TREATMENT RESPONSE;

ANIMALS; ANTIPSYCHOTIC AGENTS; ENZYME INHIBITORS; HISTONE DEACETYLASE 2; HUMANS; SCHIZOPHRENIA;

EID: 84871594405     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.12.141     Document Type: Review

References (20)

1. Kurita M, Holloway T, García-Bea A et al. HDAC2 regulates atypical antipsychotic responses through the modulation of mGlu2 promoter activity. Nat. Neurosci. 15(9), 1245-1254 (2012).
2. Marder E. Neuromodulation of neuronal circuits: back to the future. Neuron 76(1), 1-11 (2012).
3. Borrelli E, Nestler EJ, Allis CD, Sassone-Corsi P. Decoding the epigenetic language of neuronal plasticity. Neuron 60(6), 961-974 (2008).
4. Dobbs D. Schizophrenia: the making of a troubled mind. Nature 468(7321), 154-156 (2010).
5. Lieberman JA, Stroup TS, McEvoy JP et al.; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 353(12), 1209-1223 (2005).
6. Goldberg TE, Greenberg RD, Griffin SJ et al. The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia. Br. J. Psychiatry 162, 43-48 (1993).
7. Addy N, Levin ED. Nicotine interactions with haloperidol, clozapine and risperidone and working memory function in rats. Neuropsychopharmacology 27(4), 534-541 (2002).
8. Dong E, Nelson M, Grayson DR, Costa E, Guidotti A. Clozapine and sulpiride but not haloperidol or olanzapine activate brain DNA demethylation. Proc. Natl Acad. Sci. USA 105(36), 13614-13619 (2008).
9. Geyer MA, Vollenweider FX. Serotonin research: contributions to understanding psychoses. Trends Pharmacol. Sci. 29(9), 445-453 (2008).
10. Miyamoto S, Miyake N, Jarskog LF, Fleischhacker WW, Lieberman JA. Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. Mol. Psychiatry 17(12), 1206-1227 (2012).
11. González-Maeso J, Weisstaub NV, Zhou M et al. Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior. Neuron 53(3), 439-452 (2007).
12. Vollenweider FX, Vollenweider-Scherpenhuyzen MF, Bäbler A, Vogel H, Hell D. Psilocybin induces schizophrenialike psychosis in humans via a serotonin-2 agonist action. Neuroreport 9(17), 3897-3902 (1998).
13. Moreno JL, Sealfon SC, González-Maeso J. Group II metabotropic glutamate receptors and schizophrenia. Cell. Mol. Life Sci. 66(23), 3777-3785 (2009).
14. González-Maeso J, Ang RL, Yuen T et al. Identification of a serotonin/glutamate receptor complex implicated in psychosis. Nature 452(7183), 93-97 (2008).
15. Fribourg M, Moreno JL, Holloway T et al. Decoding the signaling of a GPCR heteromeric complex reveals a unifying mechanism of action of antipsychotic drugs. Cell 147(5), 1011-1023 (2011).
16. Casey DE, Daniel DG, Tamminga C et al. Divalproex ER combined with olanzapine or risperidone for treatment of acute exacerbations of schizophrenia. Neuropsychopharmacology 34(5), 1330-1338 (2009).
17. Citrome L, Casey DE, Daniel DG, Wozniak P, Kochan LD, Tracy KA. Adjunctive divalproex and hostility among patients with schizophrenia receiving olanzapine or risperidone. Psychiatr. Serv. 55(3), 290-294 (2004).
18. Meltzer HY, Bonaccorso S, Bobo WV, Chen Y, Jayathilake K. A 12-month randomized, open-label study of the metabolic effects of olanzapine and risperidone in psychotic patients: influence of valproic acid augmentation. J. Clin. Psychiatry 72(12), 1602-1610 (2011).
19. Suzuki T, Uchida H, Takeuchi H et al. Augmentation of atypical antipsychotics with valproic acid. An open-label study for most difficult patients with schizophrenia. Hum. Psychopharmacol. 24(8), 628-638 (2009).
20. Kelly DL, Conley RR, Feldman S, Yu Y, McMahon RP, Richardson CM. Adjunct divalproex or lithium to clozapine in treatment-resistant schizophrenia. Psychiatr. Q. 77(1), 81-95 (2006).